PO-1028: Consolidation therapy with Durvalumab after radical CRT in stage IIII NSCLC: a preliminar analysis.

Autor: Borghetti, P. (AUTHOR), Volpi, G. (AUTHOR), Imbrescia, J. (AUTHOR), Bonù, M.L. (AUTHOR), Guerini, A. (AUTHOR), Turla, O. (AUTHOR), Maddalo, M. (AUTHOR), Vitali, P. (AUTHOR), Triggiani, L. (AUTHOR), Donofrio, A. (AUTHOR), Buglione, M. (AUTHOR), Magrini, S.M. (AUTHOR)
Zdroj: Radiotherapy & Oncology. 2020 Supplement 1, Vol. 152, pS547-S548. 2p.
Databáze: Academic Search Ultimate
Externí odkaz: